ALNY vs CRNX
ALNY: Alnylam is a pioneer in RNA interference (RNAi) therapeutics, using gene-silencing technology to treat rare genetic diseases and cardiovascular conditions. CRNX: Crinetics Pharmaceuticals is a clinical-stage biotechnology company developing small molecule precision medicines for rare endocrine diseases and related tumors.
Side-by-side fundamentals
| Metric | ALNY | CRNX | Edge |
|---|---|---|---|
| Price as of 2026-08-04 close | $219.00 | $83.86 | |
| Market cap as of 2026-08-05 | $29.3B | $8.8B | |
| P/E as of 2026-08-05 | 36.48 | n/a | |
| PEG as of 2026-08-05 | 0.75 | -0.73 | CRNX lower |
| Net margin as of 2026-08-05 | +16.8% | -2747.2% | ALNY higher |
| Gross margin as of 2026-08-05 | +79.7% | +86.0% | CRNX higher |
| Operating margin as of 2026-08-05 | +19.9% | -3020.3% | ALNY higher |
| ROE as of 2026-08-05 | +93.6% | -44.0% | ALNY higher |
| ROA as of 2026-08-05 | +15.8% | -39.6% | ALNY higher |
| Debt / equity as of 2026-08-05 | 2.02 | 0.00 | CRNX lower |
| Revenue growth (YoY) as of 2026-08-05 | +95.1% | +2277.5% | CRNX higher |
| Revenue CAGR (3y) SEC XBRL | +53.0% | n/a | |
| Beta as of 2026-08-05 | 0.23 | 0.02 | |
| 1-year return as of 2026-08-04 close | -47.8% | +197.2% | CRNX higher |
Fundamentals: market data, as of 2026-08-05. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-04.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.